Research into genome editing is booming. So is a debate about its boundaries, what's safe and what's ethical to try in the quest to fight disease.
WASHINGTON (AP) — The hottest tool in biology has scientists using words like revolutionary as they describe the long-term potential: wiping out certain mosquitoes that carry malaria, treating genetic diseases like sickle-cell, preventing babies from inheriting a life-threatening disorder.
It may sound like science fiction, but research into genome editing is booming. So is a debate about its boundaries, what’s safe and what’s ethical to try in the quest to fight disease.
Does the promise warrant experimenting with human embryos? Researchers in China already have, and they’re poised to in Britain.
Should we change people’s genes in a way that passes traits to future generations? Beyond medicine, what about the environmental effects if, say, altered mosquitoes escape before we know how to use them?
Most Read Local Stories
- Inslee sets goal of 45,000 COVID-19 vaccinations a day in Washington; everyone 65 and older eligible now
- Body cam footage captures Seattle officers directing homeless person to Cal Anderson Park for services
- How to know when it's your turn to get a coronavirus vaccine
- Coronavirus daily news updates, January 18: What to know today about COVID-19 in the Seattle area, Washington state and the world
- Seattle's weather will get colder, but will we get snow? Here's what to expect this week
“We need to try to get the balance right,” said University of California, Berkeley, biochemist Jennifer Doudna, who helped develop new gene-editing technology.
The U.S. National Academies of Science, Engineering and Medicine will bring international scientists, ethicists and regulators together in December to start determining that balance. The biggest debate is whether it ever will be appropriate to alter human heredity by editing an embryo’s genes.
“This isn’t a conversation on a cloud,” but something that families battling devastating rare diseases may want, Dr. George Daley of Boston Children’s Hospital told specialists who met this week to plan the ethics summit. “There will be a drive to move this forward.”
Laboratories worldwide are embracing a technology to precisely edit genes inside living cells — turning them off or on, repairing or modifying them — like a biological version of cut-and-paste software. Researchers are building stronger immune cells, fighting muscular dystrophy in mice, and growing human-like organs in pigs for possible transplant. Biotech companies have raised millions to develop therapies for sickle cell disease and other disorders.
The technique has a wonky name — CRISPR-Cas9 — and a humble beginning.
Doudna was studying how bacteria recognize and disable viral invaders, using a protein she calls “a genetic scalpel” to slice DNA. That system turned out to be programmable, she reported in 2012, letting scientists target virtually any gene in many species using a tailored CRISPR recipe.
“It’s transforming almost every aspect of biology right now,” said National Institutes of Health genomics specialist Shawn Burgess.
Its biggest use has nothing to do with human embryos. Scientists are engineering animals with human-like disorders more easily than ever before, to learn to fix genes gone awry and test potential drugs.
Engineering rodents to harbor autism-related genes once took a year. It takes weeks with CRISPR, said bioengineer Feng Zhang of the Broad Institute at MIT and Harvard, who also helped develop, and patented, the CRISPR technique. (Doudna’s university is challenging the patent.)
Experts predict the first attempt to treat people will be for blood-related diseases such as sickle cell, caused by a single gene defect that’s easy to reach.
“It’s like a race. Will the research provide a cure while we’re still alive?” asked Robert Rosen of Chicago, who has a rare bone marrow abnormality that can lead to leukemia or other life-threatening conditions. He co-founded the MPN Research Foundation, which has funded some CRISPR-related studies.
So why the controversy? CRISPR made headlines last spring when Chinese scientists reported the first-known attempt to edit human embryos, working with unusable fertility clinic leftovers. They aimed to correct a deadly disease-causing gene but it worked in only a few embryos and others developed unintended mutations, raising fears of fixing one disease only to cause another.
If ever deemed safe enough to try in pregnancy, that type of gene change could be passed on to later generations. Then there are questions about designer babies, altered for other reasons than preventing disease.
In the U.S., NIH has said it won’t fund such research in human embryos.
In Britain, regulators are considering researchers’ request to gene-edit human embryos — in lab dishes only — for a very different reason, to study early development.
Medicine aside, another issue is environmental: altering insects or plants in a way that ensures they pass genetic changes through wild populations as they reproduce. These engineered “gene drives” are in very early-stage research, too, but one day might be used to eliminate invasive plants, make it harder for mosquitoes to carry malaria or even spread a defect that gradually kills off the main malaria-carrying species, said Kevin Esvelt of Harvard’s Wyss Institute for Biologically Inspired Engineering.
No one knows how that might also affect habitats, Esvelt said. His team is calling for the public to weigh in and for scientists to take special precautions.
Human gene-editing initiative: http://www.nationalacademies.org/gene-editing/index.htm